RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Europe10 was abolutely rightMaybe we'd all agree LOXO was an amazing recent success. In spring 2018 the stock peaked at $180. Over the next 6 months the SP dropped to $130 and a financing was done at that price in Oct 2018. Several months later it sells for $240. I'm sure if you bought at $130-180 range in late 2017/early 2018 then you're probably worried about a financing at $130 in Oct.
I would say LOXO had an almost perefect clinical run. After the first 7 patients they had very strong responses and that continued through the rest of the program. That didnt stop to SP from also drifting lower over 12 months from over $30 to under $20 in 2015-2016.
I dont think IMV had a perfect 2018 from a clinical perspective. They lost an important partner and their most advanced program 'stalled' as it shifted from a combo to monotherapy trial. The basket trial failed to recruit its first patient (I think we are still waiting for that). The keytruda/ ovarian hasnt reported (that has outside sponsorship), we're waiting on a DLBCL update. Put together I'd characterize that as slipping from the perfect path we might have hoped for at the start of 2018. Having said all that they also had some real success which means that we are far from complete failure.
Nobody is happy with todays news, unless you're sitting on the sidelines waiting to buy. It probably accurately reflects a mixed 2018. We're invested in biotech, its extremely risky, extremely uncertain, extremely volitile and hard to pin down valuations.
You're too binary. Management havent gone from good people to snakes with todays news, the company hasnt gone from potential big $$$$ to failure. Its reflects a period of weakness which is not unfamilar for biotechs investing.
simmer1965 wrote: waiting for you to show me one example. Europe10 is a child who couldn't answer his bs statement. can someone show me a company with exciting products and potential that raised $ @ 20% discount to thier previous months ave price???: